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Background: Dysregulation of the hypothalamic–pituitary–adrenal (HPA) axis is often 
encountered in diabetes, leading to several clinical complications. Our recent results 
showing an elevated tetrahydrocortisol/tetrahydrocorticosterone ratio in morning urine 
of diabetic children compared to that of controls suggest an increased nocturnal activity 
of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) in the former.
Question: We hypothesized that these observations could be explained by a reduced 
inhibition of hepatic 11β-HSD1 activity by exogenous insulin owing to its subcutaneous 
(SC) administration and absence of first hepatic passage. Additionally, we hypothesized 
that hippocampal 11β-HSD1 activity might also be impaired by diabetes.
Methods: We therefore measured HPA axis activity and 11β-HSD1 expression and 
activity in liver and hippocampus in streptozotocin-induced diabetic juvenile rats treated 
with SC or intraperitoneal (IP) insulin.
results: Plasma corticosterone levels were elevated in untreated diabetic rats during 
the resting phase and restored by both types of insulin treatment. The mRNA expression 
and activity of 11β-HSD1 were increased in the untreated diabetic group in liver. Although 
diabetes was controlled equally whatever the route of insulin administration, liver 11β-
HSD1 gene expression and activity was decreased only in the IP group, suggesting 
that a first hepatic pass is needed for 11β-HSD1 hepatic inhibition. In hippocampus, 
11β-HSD1 activity was elevated in the untreated diabetic group but restored by both 
types of insulin treatment. Thus, these data extend our findings in diabetic children by 
showing impairment of hippocampal 11β-HSD1 in diabetes and by demonstrating that 
IP is preferable to SC insulin administration to restore 11β-HSD1 activity in liver.
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inTrODUcTiOn
The incidence of type 1 diabetes mellitus (T1D) in children is 
increasing worldwide, particularly in children under 5 years of 
age (1). Patients and animals with poorly controlled diabetes 
show dysregulation of their hypothalamic–pituitary–adrenal 
(HPA) axis (2), and this dysfunction can be involved in complica-
tions of diabetes, such as cognitive impairment (3). To further 
understand the impairment of the HPA axis that occurs in 
diabetes, we recently studied the nocturnal tetrahydrocortisol/
tetrahydrocorticosterone (THFs/THE) ratio in children with 
T1D since it reflects 11β-hydroxysteroid dehydrogenase type 1 
(11β-HSD1) activity in most cases (4). The 11β-HSD1 enzyme 
plays a crucial role in the bioavailability of glucocorticoids by 
regenerating inactive cortisone into active cortisol in humans and 
inactive dehydrocorticosterone into corticosterone in rodents 
(5). Our recent study suggested an increased nocturnal activity 
of 11β-HSD1 in diabetic children compared to controls, since 
THFs/THE ratio was elevated in the morning urine of diabetic 
children (4). One possible explanation for this is a reduced 
inhibition of hepatic 11β-HSD1 activity by exogenous insulin 
(6) owing to its subcutaneous (SC) route and thus the absence 
of a first hepatic pass. To test this hypothesis, we measured the 
HPA axis activity and 11β-HSD1 liver expression and activity 
in streptozotocin-induced diabetic juvenile rats treated with 
either SC or intraperitoneal (IP) insulin. As HPA axis has been 
suggested to be involved in cognitive and emotional disorders in 
T1D patients (7, 8), and hippocampal 11β-HSD1 to be implicated 
in neurological disorders (9, 10), we also explored the effects of 




Male Wistar rats were purchased from Janvier (Saint Berthevin, 
France). Weaning rats (3-week-old, 50–55  g, n  =  48) were 
housed four per cage in a room with a constant airflow system 
and controlled temperature (21–23°C) and were weighed 
throughout the protocol. They were acclimatized for 7 days to 
a reverse 12-h light cycle (lights off at 10:00 a.m.) in order to 
administer insulin during the active feeding phase and to avoid 
hypoglycemia. Rats (n = 36) were treated with streptozotocin 
on day 0 (IP 65  mg/kg, citrate buffer 0.1  M pH 4.5). The 12 
remaining rats formed the control group (0.1 ml IP injection of 
vehicle). Blood glucose was measured 3 days after streptozotocin 
injection (Glucometer Freestyle, Abbott Diabetes Care Ltd., 
Alameda, CA, USA), and rats that showed hyperglycemia > 
200 mg/dl were considered diabetic. These rats were then split 
into 3 groups of 12 individuals: a group of untreated diabet-
ics (diabetics NT), a diabetic group treated with SC insulin 
(Lantus®, insulin glargine from Sanofi, Paris, France), and a 
diabetic group treated with IP insulin. Doses of insulin were 
adapted to the glycemic response of each animal. At the end of 
the experiment, in the morning, 1 week after glycemia control 
had been obtained, animals were killed by decapitation. Liver 
and hippocampus were collected from each rat and immediately 
frozen at −80°C. In order to measure plasma corticosterone, 
one blood sample was collected once in the morning at 10:00 
a.m. (end of the resting period) and once in the evening at 
10:00 p.m. (end of the active period) 2  days before sacrifice. 
Blood was collected in EDTA-coated tubes and centrifuged at 
4,000 × g for 10 min at 4°C in order to obtain plasma, which 
was stored at −80°C.
Plasma Fructosamine
Plasma fructosamine concentration to assess short-term glyce-
mic control was measured by using a glycated serum protein test 
as described in Ref. (11). Fructosamine is a marker for glycemic 
control in short term (2–3  weeks). Concentration was meas-
ured using an enzymatic method RANDOX, with proteinase 
K digesting glycated serum proteins into glycated peptide frag-
ments (GPF). This method also uses a specific fructosaminase 
(fructosylamino-oxydase) to catalyze oxidative degradation of 
GPF into protein fragments or amino-acids, glucosone, and 
hydrogen peroxide. H2O2 is measured using a Trinder colorimet-
ric reaction, and absorbance is proportional to sample’s glycated 
protein concentration.
Plasma corticosterone
Plasma corticosterone was measured with an in-house radio-
immunoassay as described in Ref. (12), using a highly specific 
antibody provided by H. Vaudry (University of Rouen, France). 
Briefly, after steroid extraction of plasma samples with absolute 
ethanol, total corticosterone was measured by competition 
between cold corticosterone and 3H-corticosterone for the spe-
cific anti-corticosterone antibody.
11β-hsD1 gene expression (rT-Pcr)
Total RNA was extracted from liver and hippocampus and 
reverse-transcribed as detailed before (13). RNA was extracted 
with a Trizol® extraction kit (Invitrogen, Saint Aubin, France) 
according to the manufacturer’s recommendations. Samples 
in a final volume of 50  µl were treated with DNAse (Turbo 
DNA free kit, Ambion, Invitrogen) for 20 min at 37°C. RNAs 
were quantified by spectrophotometry using a Nanodrop 1000 
Thermo Scientific, and their quality was assessed on Agilent 
RNA 6000 nano chips with an Agilent 2100 Bioanalyzer. Reverse 
transcription took place on aliquots of total RNA of 2 µg using 
a Superscript III Invitrogen kit containing oligohexameres, 
dNTP, and sterile water. RNA was denatured by heating at 
65°C for 5  min. RT reactions were conducted in a buffer at 
50°C for 55  min and terminated by heating at 85°C for 5  min 
followed by cooling at 4°C. mRNA levels were measured in 
real-time PCR using SYBR® green 1 as the fluorescent marker. 
Sequences of primers for the 18S housekeeping gene were 
forward 5′ACCGCAGCTAGGAATAATGGA3′ and reverse 
5′GCCTCAGTTCCGAAAACCAA3′, and for the 11β-HSD1 
gene, forward 5′TGGAAGACATGGCTTTTGCA3′ and reverse 
5′TCCAGTCCACCCAAGAGCTT3′. The relative mRNA expres - 
sion level of the target gene was expressed as 2−ΔΔCT in compari-
son with the mean ΔCT of the control group.
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11β-hsD1 activity
11β-hydroxysteroid dehydrogenase type 1 activity was measured 
in rat liver and hippocampus homogenates obtained and treated 
as described by others (14). 11β-HSD1 activity was measured in 
rat liver and hippocampus homogenates, obtained by grinding 
the samples with a tissue-lyser in a buffer containing protease 
and phosphatase inhibitors [glycerol (1.37 M), NaCl (300 mM), 
EDTA (1 mM), Tris (50 mM), PIC 1X (protease inhibitor cock-
tail), NaOV (2 mM), and NaF (1 mM), pH 7.7]. Total quantity 
of proteins of the homogenate was then measured by color-
imetry with a BCA protein assay (Bio-Rad protein assay kit) 
and a 560  nm microplaque spectrophotometer (Wallac 1420 
VICTOR3). Aliquots of each homogenate were prepared with 
a protein concentration of 0.1  mg/ml. Aliquots were then 
incubated for 30 min at 37°C with 100 nM of tritium-marked 
corticosterone (Perkin Elmer) and an excess of the 11β-HSD-
specific cofactor NADP+ (Sigma, 2 mM for liver, 400 µM for hip-
pocampus). Samples were put on ice, and steroids were extracted 
with ethyl acetate. Samples were then dried in a Speedvac at 
50°C for 30 min and dissolved in 60 µl ethanol. Steroids were 
separated by thin-layer chromatography (TLC Silica Gel 60 
F254, VWR) with chloroform and ethanol as the mobile phase 
(92% chloroform, 8% ethanol). Two steroids were separated: 
3H-corticosterone (substrate, B) and 3H-dehydrocorticosterone 
(product, A). Fractional conversion of steroids was calculated 
after scanning analysis using a β-IMAGER-2000 Phosphor 
Image Scanner in the same time as an increasing scale of 
tritium corticosterone concentrations (0.1–100  nCi). Steroids 
were identified comparing their migration and quantified 
using βVISION+ software program. 11β-HSD1 reductase 
activity was expressed as the ratio of dehydrocorticosterone/
(corticosterone + dehydrocorticosterone).
Data analysis
Data were analyzed with Statistica software. Results were 
expressed as means  ±  SEMs. Body weight was analyzed by 
a two-way ANOVA with treatment as the between factor and 
time as the repeated factor. Other data were analyzed by a one-
way ANOVA (between factor: treatment). Subsequently, when 
ANOVA was significant (p < 0.05), Fisher post hoc analyses were 
conducted.
resUlTs
Diabetes induction and insulin control
The dose of insulin received was not different between diabetic 
SC and IP rat groups throughout the experiment (3.29  ±  0.61 
vs. 3.86 ± 0.90 UI/day, respectively, per group at the end of the 
experiment, NS). At the end of the experiment, the diabetic NT 
rats showed a lower weight than controls (p < 0.05, globally). SC 
and IP insulin administration normalized the weight of diabetic 
NT rats (Figure 1A).
Fructosamine increased in the diabetic NT, SC, and IP groups 
compared to the control group (p  <  0.001, Figure  1B). Both 
insulin treatments led to a significant decrease in fructosamine 
compared to the diabetic NT group (p < 0.001).
Plasma corticosterone
Total corticosterone increased during the active phase compared 
to the resting (inactive) phase (p < 0.001) in all groups (Figure 2). 
Corticosterone was elevated in the diabetic NT group during the 
resting phase compared to the control group (p  <  0.05). This 
increase was normalized in the diabetic SC (p  <  0.01) and IP 
(p < 0.001) groups. Corticosterone was lower in the diabetic IP 
group than in the SC group (p < 0.05). No significant difference 
in corticosterone levels between groups were found by ANOVA 
during the active phase.
liver 11β-hsD1 gene expression  
and activity
ANOVA revealed a strong main effect of treatment (p < 0.001) on 
11β-HSD1 gene expression in liver (Figure 3). The diabetic NT 
group showed a significant increase in 11β-HSD1 liver mRNA 
expression (p  <  0.05), which was significantly lowered in the 
diabetic IP group compared to the diabetic NT and SC groups 
(p  <  0.001 and p  <  0.05, respectively). The diabetic SC group 
presented a higher variability with 11β-HSD1 liver mRNA expres-
sion intermediate between controls and NT diabetic rats and not 
significantly different from any of these groups (Figure 3A). The 
same pattern was found for 11β-HSD1 activity in liver. Diabetic 
NT rats showed increased liver 11β-HSD1 activity vs. the control 
group (p < 0.01). Diabetic IP group had lower 11β-HSD1 activity 
compared to the other groups (p < 0.001), while diabetic SC rats 
were not different from controls and diabetic NT (Figure 3B).
hippocampus 11β-hsD1 gene expression 
and activity
There was no statistical difference in hippocampal 11β-HSD1 
mRNA expression between the groups (Figure  4A). However, 
11β-HSD1 activity measured in hippocampus showed a signifi-
cant main treatment effect (p < 0.01). Diabetic NT rats presented 
an increased 11β-HSD1 activity (p < 0.05) compared to controls, 
which was normalized by insulin treatments more significantly in 
the IP (p < 0.001) than in the SC groups (p < 0.01) (Figure 4B).
DiscUssiOn
Following on from our previous study in children with diabetes, 
we examined in the present study possible impairments of corti-
costerone levels and of liver 11β-HSD1 in diabetic juvenile rats. 
We also studied the effect of different route of insulin administra-
tion on 11β-HSD1 expression and activity with the hypothesis 
that SC insulin administration is not efficient to inhibit 11β-HSD1 
in liver because of the absence of first hepatic passage. Finally, 
we explored 11β-HSD1 in hippocampus because hippocampal 
11β-HSD1 is known to be involved in cognitive impairment 
during aging (9) and thus might play also a role in the cognitive 
impairments associated with T1D.
As expected, untreated diabetic rats have a lower weight and 
higher glycemia than controls, associated with increased corti-
costerone levels during the resting phase and higher 11β-HSD1 
mRNA and activity in liver measured at the end of the resting 
phase. Lack of insulin is known to lead to a hypercatabolic state 
FigUre 3 | 11β-hsD1 expression and activity (percent conversion) in liver. 11β-HSD1, 11β-hydroxysteroid dehydrogenase type 1; Diabetics NT,  
untreated diabetic rats; Diabetics SC, diabetic rats treated with subcutaneous insulin; Diabetics IP, diabetic rats treated with intraperitoneal insulin. Mean ± SEM, 
*p < 0.05, **p < 0.01, ***p < 0.001 compared to the control group, §§§p < 0.001 compared to the NT group, #p < 0.05, ###p < 0.001 compared to the subcutaneous 
group. (a) 11β-HSD1 expression in liver. (B) 11β-HSD1 activity in liver.
FigUre 2 | Plasma corticosterone. Diabetics NT, untreated diabetic rats; Diabetics SC, diabetic rats treated with subcutaneous insulin; Diabetics IP, diabetic rats 
treated with intraperitoneal insulin. Mean ± SEM, **p < 0.01 compared to the control group, §§p < 0.01, §§§p < 0.001 compared to the NT group, #p < 0.05 
compared to the subcutaneous group.
FigUre 1 | Body weight at the end of the experiment (a) and plasma fructosamine at sacrifice (B). Diabetics NT, untreated diabetic rats; Diabetics SC, 
diabetic rats treated with subcutaneous insulin; Diabetics IP, diabetic rats treated with intraperitoneal insulin. Mean ± SEM, ***p < 0.001 compared to the control 
group, §p < 0.05, §§§p < 0.001 compared to the NT group.
4
Rougeon et al. Insulin Injection Routes and 11β-HSD1
Frontiers in Endocrinology | www.frontiersin.org April 2017 | Volume 8 | Article 81
illustrated by the failure to thrive. This stress probably activates 
the HPA axis centrally and increases plasma corticosterone levels. 
Increased liver 11β-HSD1 activity probably also contributes to 
the elevated corticosterone levels in diabetic rats.
Interestingly, while no significant differences were observed 
during the active phase, the resting phase appeared to be more 
sensitive for differentiating HPA axis activity between the groups. 
Furthermore, increased 11β-HSD1 activity during the resting 
phase is in line with our findings in diabetic children in whom 
11β-HSD1 activity was found increased in urine collected during 
the night (4). Since others did not find any difference over 24 h of 
urine collection (15), these findings in children and in the present 
animal study underline the need to take into account the phase 
of the nycthemeral cycle in which HPA axis activity is studied. 
FigUre 4 | 11β-hsD1 expression and activity (percent conversion) in hippocampus. 11β-HSD1, 11β-hydroxysteroid dehydrogenase type 1; Diabetics NT, 
untreated diabetic rats; Diabetics SC, diabetic rats treated with subcutaneous insulin; Diabetics IP, diabetic rats treated with intraperitoneal insulin. Mean ± SEM, 
*p < 0.05, **p < 0.01, when compared to the control group, §§p < 0.01, §§§p < 0.001 when compared to the NT group. (a) 11β-HSD1 expression in hippocampus.  
(B) 11β-HSD1 activity in hippocampus.
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Functionally, increased corticosterone levels at time of secretion 
nadir results in a globally flattened circadian secretion of the 
hormone that is known to have deleterious consequences on the 
body as well as on the brain (16). Of note, hippocampal 11β-HSD1 
activity was also found elevated in diabetic untreated animals. 
Since 11β-HSD1 increases local corticosterone levels, it may fur-
ther contribute to cognitive impairments in T1D in addition to the 
lack of insulin and to dysregulated systemic corticosterone levels.
Although we obtained the same level of glycemic control of 
diabetes, assessed by glucose and fructosamine levels, between 
the SC vs. IP insulin-treated groups, 11β-HSD1 gene expres-
sion and activity were significantly decreased only in the IP 
insulin-treated group in liver. This result supports our hypothesis 
that a first hepatic pass may be needed for efficient 11β-HSD1 
hepatic inhibition, which would not be achieved efficiently by 
SC insulin treatment. Further investigations are required to 
prove the hypothesis. Furthermore, the effects of insulin could 
be indirect, for instance, by being mediated by an increase in 
growth hormone (GH) activity, which was described to inhibit 
11β-HSD1 activity (17), whereas insulin increases levels of GH 
receptors (18). By reducing the hypercatabolic state and then 
limiting stress-induced HPA axis central activation, SC insulin 
treatment normalized plasma corticosterone levels in the resting 
state. Interestingly, IP insulin treatment decreased plasma corti-
costerone levels even more than SC. This effect could be linked in 
part to the inhibition of hepatic 11β-HSD1 activity that is clearly 
more efficient in IP vs. SC insulin administration. This finding 
could further support the use of IP insulin delivery that has shown 
numerous benefits in other studies (lower peripheral insulinemia, 
better reproducibility of insulin profiles, and improved glucagon 
response to hypoglycemia) owing to a pharmacokinetic that is 
closer to the physiological state than the SC route (19).
In conclusion, the present findings extend our data reported 
in diabetic children in that diabetes leads to an increase of 11β-
HSD1 activity not only in liver but also in hippocampus. Our data 
suggest a new potential benefit of the IP route of insulin treatment. 
By better limiting the regeneration of active glucocorticoids in 
the liver of diabetic patients, it could also have a positive impact 
on complications that occur as a result of dysregulation of the 
corticotropic axis.
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